Sul	bstitute for form 1449A/PTO				OMPLETE IF KNOWN	
II	NFORMATION I	DISCLOSURE		Application Number	10/573,108	
	TATEMENT BY		•	Filing Date	March 23, 2006	
		2222	1	First Named Inventor	Wallace T. Ashton	
	. Bases	104 0 , 522		Group Art Unit	To be Assigned	
	(use as many sheets	as precessary)	5/	Examiner Name	To be Assigned	
Sheet	1	of 5		Attorney Docket Number	21562P	

			U.S. PA	TENT DOCUMENTS	
Examiner nitials*	Cite No.	U.S. Patent Document Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
/FTP/	1	6,699,871 B2		Edmondson et al.	03/02/2004
	2	6,011,155		Villhauer	01/04/2000
	3	6,166,063		Villhauer	12/26/2000
	4	5,939,560		Jenkins et al.	08/17/1999
	5	6,303,661 B1		Demuth et al.	10/16/2001
•	6	6,432,969 B1		Villhauer	08/13/2002
/FTP/	7	4,386,090		Moinet et al	05/31/1983
			Ī		
					-
_					

			FOREIG	GN PATENT	T DOCUMENTS		
Examiner	Cite		Foreign Patent Document		Name of Retenton or Applicant	Date of Publication of	
lnitials*	No.	Office Number		Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY	
	8	PCT W	9-03/002017-A2		MERCK & CO., INC.	10/09/2003	
	<u> </u>	PCT W	2 03/000180 A2		MERCK & CO., DIC.	01/03/2003	
	10	PCT W	9 03/000181 A2		MERCK & CO., INC.	01/03/3003	
	11	PCT W	0.02/000181 4.2		MERCY & CO, DIC	01/02/2002	
	12	PCT WO	7 02/070430 A I		WERCK & CO., INC.	10/03/2002	
	13	PCT W	2004/007468 A1		MERCK & CO., INC.	01/22/2004	
	14	PCT W	2004/032830 A2		MERCK & CO., INC.	04/22/2004	
	15		2004/050022 A2		MERCK & CO., INC.	00/17/2004	
	16		2004/058266 A1		MERCK & CO., INC.	07/15/2004	
	17	PCT WC	2004/064 / 78 AZ		MERCK & CO., INC.	08/03/2004	

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form* IDS Form* (IDS Folder), Merth & Co., Inc., -7/12/2005

^{*}Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

	Substitute for form 1449A/PTO		,	COMPLETE IF KNOWN				
	INFORMATION	DISC	CLOSURE	Application Number	10/573,108			
		DY	NI KOLABITE	Filing Date	March 23, 2006			
1	STATEMENT BY	API	LICANI	First Named Inventor	Wallace T. Ashton, et al			
			,	Group Art Unit	To Be Assigned			
	use as many sheets	s as ne	cessary)	Examiner Name	To Be Assigned			
Shee	2	of	5	Attorney Docket Number	21562P			

			U.S. P.	ATENT DOCUMENTS
Examiner Initials®	Cite No.	U.S. Patent Document	Kind Code (if known)	Date of Publication of
W 1.				
•				
-				
		•		

			FOREIC	IN PATENT	T DOCUMENTS	
Examiner Initials*	Cite No.	Office	Foreign Parent Document	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
	18	PCT	WO 2004/069162 A2		MERCK & CO., INC.	08/19/2004
	19	PCT	WO 02/02560 A2		NOVO NORDISK A/S	01/10/2002
	20	PCT	WG 01/96295 A2		NOVARTIS AG	12/20/2001
	21	PCT	XO 01/96295 A3		NOVARTIS AG	12/20/2001
	22	PCZ	WO 01/34594 A1		Guilford Pharmaceuticals, Inc.	05/17/2001
	23	y CT	WO 00/34241		NOVARTIS AG	06/15/2000
	24	PCT	WO 98/19998 A2		NOVARTIS AG	05/14/1998
	2/	PCT	WO 98/19998 A3		NOVARTIS AG	05/14/1998
	26	PCT	WO 97/40832		Hansknoll-Institut Fur Naturstoff-Forschung E.V.	11/06/1997
	27	PCT	WO 03/000180 A3		MERCK & CO., INC.	01/03/2003

^{*}Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

	Substitute for form 1449A/PTO				COMPLETE IF KNOWN	
	INFORMATIO		LOSURE	Application Number	10/573,108	
				Filing Date	March 23, 2006	
'	STATEMENT I	SY APPI	LICANT	First Named Inventor	Wallace T. Ashton et al	
				Group Art Unit	To Be Assigned	
	(see as many she	ets as nece	essary)	Examiner Name	To Be Assigned	
She	et 3	of	5	Attorney Docket Number	21562P	

			U.S. PATEN	NT DOCUMENTS	
Examiner Initials*	Cite No.	U.S. Patent Docum		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY

			FOREIC	ON PATENT	DOCUMENTS		
Examiner Initials*	Cite No.	Office	Foreign Parent Document Office purnber		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	
	28	PCT	WO 02/92560	A3	NOVO NORDISK	01/10/2002	
	29	PCT	WO 94/42262		AKZO NOBEL N.V.	06/14/2001	
	30	PCT	W9 2004/043940		MERCK & CO., INC.	05/27/2004	
	31	PCT	XO 2004/007468		MERCK & CO., INC.	01/29/2004	
	32	PC	WO 2004/110436		MERCK & CO., INC.	12/23/2004	
	33	VCT	WO 2004/112701	A2	MERCK & CO., INC.	12/29/2004	
	34	PCT	WO 2004/112701	A3	MERCK & CO., INC.	12/29/2004	
	36	PCT	WO 2005/011581	A2	MERCK & CO., INC.	02/10/2005	
	36	PCT	WO 2005/044195	A2	MERCK & CO., INC.	05/19/2005	
	37	PCT	WO 2005/002530	A2	SMITHKLINE BEECHAM CORP.	01/09/2003	

^{*}Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

-						
	Substitute for form 1449A/PTO				COMPLETE IF KNOWN	
	INFORMATION	DIS	CLOSURE	Application Number	10/573,108	
	OD A DESCENIE DA	/ A TO	DI ICANIT	Filing Date	March 23, 2006	
•	STATEMENT BY	AP	PLICANI	First Named Inventor	Wallace T. Ashton, et al	
				Group Art Unit	To Be Assigned	
	(bse as many sheet	s as n	ecessary)	Examiner Name	To Be Assigned	
Shee	et 4	of	5	Attorney Docket Number	21562P	

		U	.S. P	ATENT DOCUMENTS
Examiner Initials*	Cite No.	U.S. Patent Document	Kind Code known)	Date of Publication of
•				
•			1	

			FOREI	GN PATENT	DOCUMENTS	
Examiner Initials*	Cite No.	Office	Foreign Parent Documen	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
	38	PCT	WO 2002/056003	Al	GRAFFINITY PHARMACEUTICAL	06/23/2005
	39	PCT	WO 2005/056013	A1	GRAFFINITY PHARMACEUTICAL	06/23/2005
	40	PCT	WØ 2005/108382	Al	MERCK & CO., INC.	1 17/2005
	41	PCT	WO 2005/116029	A1	MERCK & CO., INC.	12/08/2005
	42	PC	WO 2005/123685	A1	ASTRAZENECA AB	12/29/2005
	43	CT	WO 2006/009886	A1	MERCK & CO., INC.	01/26/2006
	44	PCT	WO 2006/023750	A2	MERCK & CO., INC	03/02/2006

^{*}Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449B/PTO					COMPLETE IF KNOWN			
_			N DIS	CLOSURE	Application Number	10/573,108	•	
STATEMENT BY APPLICANT					Filing Date	March 23, 2006		
					First Named Inventor	Wallace T. Ashton, et al		
				, .	Group Art Unit	To Be Assigned		
(se as many sheets as necessary)					Examiner Name	To Be Assigned		
Sheet		5	of	5	Attorney Docket Number	21562P		

		NON PATENT LITERATURE DOCUMENTS
Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.
	43	J. J. Holst, 'Treatment of Type 2 Diabetes Mellitus with Agonists of the GLP-1 Receptor or DPP-IV Inhibitors", Expert Opin. Emerg. Drugs, Vol. 9(1) pp. 155-166(2004).
	44	C. F. Deacon, et al., "Inhibitors of dipeptidyl peptidase IV: A Novel Approach for the Prevention and Treatment of Type & Diabetes?", Expert Opin. Investig. Drugs, Vol. 13(9) pp. 1091-1102(2004).
	45	K. Augustyns et al., "Dipeptidyl Peptidase IV Inhibitors as New Therapeutic Agents for the Treatment of Type 2 Diabetes", Expert Opin. Ther. Patents, Vol. 13(4), pp. 499-510(2003).
•	46	Novartis AG: WO0034241, "Novel N-substituted-2-Cyanopyrroldines as Potent Inhibitors of Dipeptidyl Peptidase IV in the Treatment of Non-Insulin-Dependent Diabetes Mellitus", Exp. Opin. Ther. Patents, Vol. 10(12), pp. 1937-1942 (2000).
•	47	D. J. Orucker, "Therapeutic potential of dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes", Exp. Opin Invest. Drugs, Val. 12, pp. 87-106 (2004).
	48	T. P. Vahl & D. A. D'Alessio, "Gut peptides in the treatment of diabetes mellitus" Exp. Opin. Invest. Drugs, Vol. 13, pp. 177-188 (2004).
	49	L. B. Knudsen, "Glucagon-like peptide-1: The Baris of a New Class of Treatment for Type 2 Diabetes", J. Med. Chem, Vol. 47, pp. 4128-4134 (2004).
	50	A. E. Weber, "Dipeptidyl Peptidase IV Inhibitors for the Treatment of Diabetes", J. Med. Chem, Vol. 47, pp. 4135-4141 (2004).
	51	J. J. Holst and C. F. Deacon, "Olucagon-like peptide 1 and inhibitors of dipeptidyl peptidase IV in the treatment of type 2 diabetes mellitus", Curr. Opin Pharmacology, Vol. 4, pp. 589-596 (2004).
	52	C. F. Deacon, "Perspectives in Diabetes - Therapeutic Strategies Based on Glucagon-Like Peptide 1", Diabetes, Vol. 53, pp. 2181-2189 (2004).
	53	K. Augustyns, et al. "Inhibitors of proline-specific dipeptidyl peptidase: DPP IV inhibitors as a novel approach for the treatment of Type 2 diabetes", Expert Opin. Ther. Patents, Vol. 15(10), pp. 1387-1407 (2005).
	54	Hans-Ulrich Demuth, et al., "Type 2 diabetes - Therapy with dipetidyl peptidase V inhibitors", Biochimica et Biophysica Acta, Vol. 1751, pp., 33-44 (2005).
	/	

Examiner Signature	/Fiona T. Powers/	Date Considered	03/27/2007